Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab + Metronomic Temozolomide in High Grade Brain Tumors
NCT07243470Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Nov 2025
- Primary completion
- Oct 2029
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in glioma, central nervous system tumor, sponsored by Centre Léon Bérard. Started Nov 2025; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
gliomacentral nervous system tumor
Beyond the preview
Go deeper on NCT07243470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243470.